Press Releases

- Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 - Strong financial position supports investment in long-term growth drivers including pipeline expansion - Initiation of Phase 1 clinical trial of shingles vaccine

EMERYVILLE, Calif. , Jan. 7, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares

EMERYVILLE, Calif. , Jan. 5, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.